Press Releases

Cepheid Expands Respiratory Disease Portfolio with Xpert Xpress Strep A

Accurate and Reliable Group A Strep Detection in as soon as 18 minutes1

SUNNYVALE, CALIF. — October 5, 2017 — Cepheid announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to market Xpert® Xpress Strep A. The test provides rapid, accurate, and reliable molecular detection of Streptococcus pyogenes (Group A β-hemolytic Streptococcus or Strep A) DNA from patient throat specimens in as little as 18 minutes for a positive result.

Read more ...

2017 launch of new TB test Ultra backed by WHO recommendation

Xpert MTB/RIF Ultra can better diagnose TB in children and people living with HIV

Sunnyvale, CA, USA; New Brunswick, NJ, USA; Geneva, Switzerland – 24 March 2017 -- On World TB Day, Cepheid, Rutgers New Jersey Medical School and FIND today announced a new version of the Xpert MTB/RIF test, the Xpert® MTB/RIF Ultra (Ultra), for the diagnosis of TB and rifampicin resistance. The World Health Organization (WHO) earlier today issued a recommendation that Ultra can be used as an alternative to the existing Xpert MTB/RIF test for the diagnosis of TB and detection of rifampicin resistance in all settings1.

Read more ...

Cepheid Announces FDA Clearance Of Xpert® Xpress Flu And Xpert Xpress Flu/RSV

Providing Rapid Molecular Diagnostic Results in as little as 20 minutes

SUNNYVALE, Calif.Feb. 15, 2017 /PRNewswire/ -- Cepheid today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market Xpert® Xpress Flu and Xpert Xpress Flu/RSV. Both tests deliver reference-quality molecular results in as little as twenty minutes. The tests are Cepheid's first Xpress branded products — all of which are expected to deliver results in 30 minutes or less.1

Read more ...

Cepheid Announces FDA Clearance of Next-Generation Test for MRSA Colonization

SUNNYVALE, Calif.Dec. 19, 2016 /PRNewswire/ -- Cepheid today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for Xpert® MRSA NxG, the next generation methicillin-resistant Staphylococcus aureus (MRSA) infection control test from the leader in healthcare-associated infection (HAI) testing. Xpert® MRSA NxG is an accurate, on-demand, molecular test that delivers actionable results in about an hour.

Read more ...

Danaher Completes Acquisition Of Cepheid

WASHINGTONNov. 4, 2016 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher") announced that today it completed its acquisition of Cepheid (NASDAQ: CPHD).

Copper Merger Sub, Inc. ("Copper"), a California corporation and an indirect wholly owned subsidiary of Danaher, has merged into Cepheid and, as a result, Cepheid has become an indirect wholly owned subsidiary of Danaher. In the merger, each outstanding share of Cepheid common stock was cancelled and (except for shares held by Danaher, Copper, Cepheid and their respective subsidiaries) converted into the right to receive $53.00 per share in cash, without interest.

Read more ...

30 Minute Or Less Molecular Flu/RSV Test Now Available Outside The US

Why Choose Between Fast or Accurate When You Can Have Both?

SUNNYVALE, Calif.Oct. 27, 2016 /PRNewswire/ -- With the flu season fast approaching, healthcare providers no longer need to choose between a fast test result or an accurate test result for patients suspected of influenza infection.  Now, they can have both, with Xpert® Xpress Flu/RSV from Cepheid (Nasdaq: CPHD), a new test that delivers reference-quality molecular test results in as little as twenty minutes.1

Read more ...

Cepheid Announces Receipt of Required Regulatory Clearances in Proposed Acquisition by Danaher Corporation

SUNNYVALE, Calif.Oct. 24, 2016 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced that antitrust clearances have been received or the requisite waiting periods have expired, as applicable, in the United StatesGermanyAustria and South Africa, which comprise all of the governmental approvals required as a closing condition pursuant to the merger agreement executed in connection with the proposed acquisition of Cepheid by Danaher Corporation.

Read more ...

New Bladder Cancer Test Could Reduce Number Of Invasive Procedures Required For Recurrence Monitoring

Xpert Bladder Cancer Monitor Now Commercially Available

SUNNYVALE, Calif.Oct. 5, 2016 /PRNewswire/ -- There's now an easier way to confidently rule out bladder cancer recurrence, thanks to a new test from Cepheid (Nasdaq: CPHD), Xpert® Bladder Cancer Monitor, now commercially available in Germany and cleared for commercial availability in all countries accepting the CE Mark. 

Read more ...

Cepheid Targets Development of a Point of Care HIV Viral Load Test From a Few Drops of Blood

Enabling Accurate and Fast Molecular HIV Viral Load Test from Finger Stick Whole Blood

SUNNYVALE, Calif., Sept. 8, 2016 /PRNewswire/ -- Millions of patients, including newborns, in primary health care settings could gain access to a potentially life-changing test for HIV viral load monitoring thanks to a new development effort from Cepheid (Nasdaq: CPHD), which is being partially funded by a grant from the Bill & Melinda Gates Foundation.

Cepheid's Xpert TV Now Cleared For Testing Symptomatic And Asymptomatic Men

First and Only Trichomonas NAAT Test with Male Urine Claims Cleared for Use in United States

SUNNYVALE, Calif., Sept. 6, 2016 /PRNewswire/ -- Men in the United States can now have easier access to fast and accurate testing for a potentially dangerous sexually transmitted infection, thanks to expanded claims allowed by the Food and Drug Administration (FDA) for the Xpert TV assay by Cepheid (Nasdaq: CPHD), a sensitive urine-based test for Trichomonas vaginalis that delivers results in as little as 35 minutes.